Q3 Earnings

Latest Headlines

Latest Headlines

Pfizer joins Q3 trend toward suffering sales

It's official. The third quarter of 2010 is pharma's period of respectable profits on weak sales. Pfizer's ($PFE) earnings, released today, confirm that trend. The drugmaker posted profits of $866

$950M Vioxx charge weighs on Merck earnings

In a couple of key respects, Merck's earnings report reads like a repeat of other Big Pharma third-quarter results. Earnings, excluding charges, were up to 85 cents per share, aided in part by the

AZ profits plummet, but Crestor shines

Blame it on Seroquel, for one thing. AstraZeneca posted a big drop in third-quarter operating profits, weighed down by a charge of $473 million to cover potential Seroquel liabilities and $212

Victoza boosts Novo as Elan, Biogen profits drop

Another mixed slate of pharma earnings today. Novo Nordisk's results shine, with an increase in both profits and sales; the Danish diabetes specialist even raised its outlook for the year. But Elan

Econo-gloom bypasses pharma earnings

Believe it or not, it's already time for Q3 earnings announcements to begin. Next week, three Big Pharmas will step into the financial limelight: Johnson & Johnson, Abbott Laboratories, and